Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 15/100

Failure Rate

9.8%

6 terminated/withdrawn out of 61 trials

Success Rate

90.2%

+3.7% vs industry average

Late-Stage Pipeline

56%

34 trials in Phase 3/4

Results Transparency

56%

31 of 55 completed trials have results

Key Signals

31 with results6 terminated

Enrollment Performance

Analytics

Phase 3

32(55.2%)

Phase 2

11(19.0%)

Phase 1

10(17.2%)

N/A

3(5.2%)

Phase 4

2(3.4%)

58Total

Phase 3(32)

Phase 2(11)

Phase 1(10)

N/A(3)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (61)

Showing 20 of 61 trials

NCT00712322Phase 2Terminated

A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity

Role: lead

NCT01400776Phase 3Completed

Safety & Efficacy WC3011 (Estradiol Vaginal Cream) in the Treatment of Vulvovaginal Atrophy in Postmenopausal Women

Role: lead

NCT01816139Phase 3Completed

Multicenter Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women

Role: lead

NCT01845649Phase 3Completed

Study to Evaluate Safety and Efficacy of WC3011 (Estradiol Vaginal Cream) in Postmenopausal Women With Dyspareunia

Role: lead

NCT01455597Phase 3Completed

Evaluate Long-Term Safety and Efficacy WC3011 (Estradiol Vaginal Cream)

Role: lead

NCT00512499Not ApplicableCompleted

Strategies to Treat Osteoporosis Following a Fragility Fracture

Role: collaborator

NCT02670785Phase 2Completed

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

Role: lead

NCT01939184Phase 2Completed

Assess Safety & Efficacy of WC3055 in Men With Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia

Role: lead

NCT00918749Phase 2Completed

Delayed Release (DR) Risedronate Compared to Immediate Release (IR) in Postmenopausal Women

Role: lead

NCT00073021Phase 3Completed

Safety and Efficacy of Two Different Doses of Asacol in the Treatment of Moderately Active Ulcerative Colitis

Role: lead

NCT01037218Phase 3Completed

Treatment of Erectile Dysfunction II

Role: lead

NCT01065012Phase 3Completed

Treatment of Erectile Dysfunction - Long Term Safety and Efficacy

Role: lead

NCT01810575Phase 2Terminated

Efficacy & Safety of Single Dose Alprostadil Cream (2 Concentrations Enhancer) to Vehicle in Men w/Erectile Dysfunction

Role: lead

NCT00837746Completed

Analysis of Iliac Crest Biopsies From Patients Receiving Risedronate

Role: lead

NCT00778154Completed

Study of Bone Histomorphometry, Microarchitecture, and Matrix Structure in Patients Receiving Alendronate or Risedronate

Role: lead

NCT00780507Completed

Fecal Biomarker Study for Patients With Ulcerative Colitis

Role: lead

NCT00577395Phase 4Terminated

Bone Microarchitecture in Osteopenic Postmenopausal Women

Role: lead

NCT00477633Phase 3Completed

Study of Safety and Efficacy of an Oral Contraceptive

Role: lead

NCT00932321Phase 3Completed

Study of Safety and Efficacy of an Oral Contraceptive

Role: lead

NCT00541658Phase 3Completed

A Study of a 35 mg Delayed Release Formulation of Risedronate for Osteoporosis

Role: lead